HomeLUPIN • NSE
add
Lupin Ltd
Previous close
₹1,941.40
Day range
₹1,924.90 - ₹1,960.00
Year range
₹1,794.05 - ₹2,402.90
Market cap
891.11B INR
Avg Volume
1.04M
P/E ratio
27.23
Dividend yield
0.61%
Primary exchange
NSE
In the news
Financials
Income Statement
Revenue
Net income
(INR) | Mar 2025info | Y/Y change |
---|---|---|
Revenue | 56.67B | 14.24% |
Operating expense | 27.10B | 22.83% |
Net income | 7.73B | 114.93% |
Net profit margin | 13.63 | 88.00% |
Earnings per share | 16.87 | 114.63% |
EBITDA | 9.65B | 4.27% |
Effective tax rate | 12.67% | — |
Balance Sheet
Total assets
Total liabilities
(INR) | Mar 2025info | Y/Y change |
---|---|---|
Cash and short-term investments | 29.90B | 46.96% |
Total assets | 292.05B | 21.70% |
Total liabilities | 119.11B | 23.76% |
Total equity | 172.94B | — |
Shares outstanding | 456.57M | — |
Price to book | 5.15 | — |
Return on assets | — | — |
Return on capital | 8.73% | — |
Cash Flow
Net change in cash
(INR) | Mar 2025info | Y/Y change |
---|---|---|
Net income | 7.73B | 114.93% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is primarily a manufacturer of generic drugs, covering therapeutic areas such as paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis. Wikipedia
Founded
1968
Headquarters
Website
Employees
24,006